Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925736 | 0.85 | OPRK1 (0.55) | PKMOPRK1PDE4DLMNAPOLB | |
| SCHEMBL11255201 | 0.84 | SRD5A1 (0.59) | OPRK1PDE4DSRD5A1SRD5A2KMT2A | |
| SCHEMBL8287657 | 0.81 | PKM (0.49) | PKMLMNAPOLBTRIM24GAA | |
| SCHEMBL30667271 | 0.81 | PKM (0.49) | PKMLMNAPOLBTRIM24GAA | |
| SCHEMBL434054 | 0.79 | TRIM24 (0.54) | PKMLMNAPOLBTRIM24GAA | |
| SCHEMBL30222138 | 0.79 | TRIM24 (0.54) | PKMLMNAPOLBTRIM24GAA | |
| SCHEMBL9918982 | 0.79 | SRD5A1 (0.50) | PKMOPRK1PDE4DGAASRD5A1 | |
| SCHEMBL26021803 | 0.78 | BMPR1B (0.48) | PKMOPRK1PDE4DLMNAPOLB | |
| SCHEMBL24430193 | 0.78 | PKM (0.59) | PKMLMNAPOLBTRIM24ALDH1A1 | |
| SCHEMBL2643055 | 0.78 | TRIM24 (0.49) | PKMLMNAPOLBTRIM24GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| EP-1874777-B1 | 1H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2011-06-08 | — | — | EP | disclosed |
| US-20090215741-A1 | 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7547706-B2 | 1H-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080125410-A1 | 7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate; 4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-pyrimido-[4,5-b]indole; Alzheimer's or Parkinson's disease | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
| EP-1874777-A1 | H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111648-A1 | H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-10-26 | — | — | WO | disclosed |
| EP-0730579-B1 | SUBSTITUTED INDOLES AS PHOSPHODIESTERASE TYPE IV INHIBITORS | PFIZER (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-0750621-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1999-07-21 | — | — | EP | disclosed |
| US-5783575-A | CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1998-07-21 | — | — | US | disclosed |
| EP-0750621-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-01-02 | — | — | EP | disclosed |
| EP-0730579-A1 | SUBSTITUTED INDOLES AS PHOSPHODIESTERASE TYPE IV INHIBITORS | PFIZER INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5536721-A | Thieno[2,3-b-indole derivatives and their use for treating central nervous system diseases related to the metabotropic glutamate receptor system | NOVO NORDISK A/S (DK) | 1996-07-16 | — | — | US | disclosed |
| US-5502072-A | INHIBITORS OF PHOSPHODIESTERASE FOT TREATMENT OF AIDS, ASTHMA, RHEUMATOID ARTHRITIS, BRONCHITIS, PSORIASIS, ANTIALLERGENS AND ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995025110-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-09-21 | — | — | WO | disclosed |
| WO-1995014667-A1 | SUBSTITUTED INDOLES AS PHOSPHODIESTERASE TYPE IV INHIBITORS | PFIZER INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5030646-A | Treatment of diseases resulting from disfunction of seretoninergic system | ADIR ET COMPAGNIE (FR) | 1991-07-09 | — | — | US | disclosed |
| US-4160032-A | Oxindoles as sleep-inducers | SANDOZ, INC. (US) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | PKM 2565/4885OPRK1 1495/4885PDE4D 4253/4885 |
| US-20090215741-A1 | 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use | IDO1, IDO2, TPH1 | PKM 1592/4885OPRK1 167/4885PDE4D 636/4885 |
| US-20080125410-A1 | 7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate; 4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-pyrimido-[4,5-b]indole; Alzheimer's or Parkinson's disease | PARK7, SNCA, PSEN2 | PKM 1814/4885OPRK1 156/4885PDE4D 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.